Correlation Engine 2.0
Clear Search sequence regions


Sizes of these terms reflect their relevance to your search.

In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine. H-gemcitabine has low toxicity because it is membrane-impermeable; however, it still has high tumor efficacy because of its ability to target gemcitabine to E-DNA in tumors. We demonstrate here that H-gemcitabine has a wider therapeutic window than free gemcitabine.

Citation

Madhuri Dasari, Abhinav P Acharya, Dongin Kim, Seungjun Lee, Sungmun Lee, Jeanne Rhea, Ross Molinaro, Niren Murthy. H-gemcitabine: a new gemcitabine prodrug for treating cancer. Bioconjugate chemistry. 2013 Jan 16;24(1):4-8

Expand section icon Mesh Tags

Expand section icon Substances


PMID: 23237198

View Full Text